Status:
COMPLETED
Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus
Lead Sponsor:
Solventum US LLC
Collaborating Sponsors:
3M
Conditions:
Staphylococcus Aureus
Eligibility:
All Genders
18+ years
Brief Summary
To establish the clinical test performance characteristics of sensitivity, specificity and predictive values for direct detection of nasal Staphylococcus aureus colonization against clinical microbiol...
Eligibility Criteria
Inclusion
- Subjects 18 years of age or older, male or female and from any race or culture.
- Subjects who are ambulatory (able to walk unaided or with a cane, walker, wheelchair) on the day of their pre-operative visit for non-emergent surgery.
Exclusion
- Subjects who are on the nasal topical antibiotic Mupirocin (Bactroban® Nasal Ointment) within the last 4 weeks.
- Subjects who are present at the preoperative visit with prescribed nasal medical devices (e.g. CPAP = Continuous Positive Airway Pressure or Nasal Cannula), nasal prosthetics, the wearing of nasal jewelry or trauma to the nose or anything that may inhibit sampling of the anterior nares.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
OBSERVATIONAL
End Date :
March 1 2007
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00406549
Start Date
December 1 2006
End Date
March 1 2007
Last Update
October 2 2024
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Hope Research Institute
Phoenix, Arizona, United States, 85017
2
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
3
Atlanta Institute for Medical Research
Decatur, Georgia, United States, 30030
4
Northwestern Univesity
Chicago, Illinois, United States, 60611